ReviewInternational journal of endocrinology2015
Noninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease.
Review in International journal of endocrinology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis.Gastroenterology · 2019Trial
- Emerging Indices Outperform Traditional Fibrosis Scores in Young Metabolic Dysfunction-Associated Steatotic Liver Disease Across Divergent Screening Goals.Journal of gastroenterology and hepatology · 2026Article
- Unravelling risk factors for delayed bleeding following ultrasonography-guided liver biopsy: a retrospective analysis.Translational gastroenterology and hepatology · 2025Article
- Metabolic dysfunction-associated steatotic liver disease: The question of long-term high-normal alanine aminotransferase as a screening test.World journal of gastroenterology · 2024Article
- Interaction between non-alcoholic fatty liver disease and obesity on the risk of developing cardiovascular diseases.Scientific reports · 2024Article
- Non-Invasive Measurement of Hepatic Fibrosis by Transient Elastography: A Narrative Review.Viruses · 2023Review
- Serum IL-27 levels increase in subjects with hypothyroidism and are negatively correlated with the occurrence of nonalcoholic fatty liver disease.Frontiers in endocrinology · 2023Article
- Article
- Ferritin as a key risk factor for nonalcoholic fatty liver disease in children with obesity.Journal of clinical laboratory analysis · 2021Article
- Assessment of non-alcoholic fatty liver disease (NAFLD) severity with novel serum-based markers: A pilot study.PloS one · 2021Article
- Association between Atrial Fibrillation and Advanced Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease.Yonsei medical journal · 2020Article
- Simple Noninvasive Scores Are Clinically Useful to Exclude, Not Predict, Advanced Fibrosis: A Study in Turkish Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease.Gut and liver · 2020Article
- Functional Microbial Responses to Alcohol Abstinence in Patients With Alcohol Use Disorder.Frontiers in physiology · 2020Article
- Serum and Fecal Oxylipins in Patients with Alcohol-Related Liver Disease.Digestive diseases and sciences · 2019Article
- Liver fibrosis is associated with risk for colorectal adenoma in patients with nonalcoholic fatty liver disease.Medicine · 2019Observational
- Article
- Correlation between Serum Ferritin Level and Histopathological Disease Severity in Non-alcoholic Fatty Liver Disease.Middle East journal of digestive diseases · 2018Article
- Clinical endpoints and adaptive clinical trials in precirrhotic nonalcoholic steatohepatitis: Facilitating development approaches for an emerging epidemic.Hepatology communications · 2017Review
- Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection.Annals of translational medicine · 2017Review
- Liver test abnormalities in patients with HIV mono-infection: assessment with simple noninvasive fibrosis markers.Annals of gastroenterology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is prevalent in 20-25% of the general population and is associated with metabolic risk factors such as obesity, diabetes mellitus, and dyslipidemia. Histologically, NAFLD ranges from simple steatosis to nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis. As NASH develops in only 10-15% of patients with NAFLD, it is not practical to biopsy all patients who present with NAFLD. Noninvasive fibrosis tests have been extensively developed recently and offer alternatives for staging fibrosis. Despite their increasing use, such tests cannot adequately differentiate simple steatosis from NASH. At present, such tests can be used as first line tests to rule out patients without advanced fibrosis and thus prevent unnecessary secondary care referrals in a significant number of patients. In this review we present the evidence for the use of noninvasive fibrosis tests in patients with NAFLD.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.